 |
|
|
 |
 |
 |
 |
Kinexum / n. 1. Connecting the important
components in health product discovery and development. 2. The
energy derived from a culture of trust, openness, collaboration, and
innovation. |
 |
|
|
 |
 |
 |
 |
 |
|
|
Kinexum Metabolics, Inc. (KMI) is dedicated to
identifying and developing metabolic and endocrine therapies in early
and mid stages of development. It seeks to develop its product
portfolio through research collaboration and in-licensing.
KMI’s scope of interest and expertise includes—
- diabetes and its complications
- obesity
- lipid disorders
- degenerative diseases and aging
- growth and development disorders
- mechanistic-based cardiovascular risk reduction, and
- inborn errors of metabolism.
KMI’s approach is to—
- identify promising, undervalued compounds in need of further
early and mid stage development
- utilize innovative clinical and regulatory strategies to achieve
speed to value
- access knowledge of experts and decision makers through long
term relationships
- operate an efficient and effective organization with minimal
overhead and resources focused on execution of clinical development
programs
|
|
|
|
|
|
|
|
|
|
|
Dr. G. Alexander Fleming, Kinexum CEO, to speak at Metabolic Summit November
1-2 in San Diego, California. Generating β-cells in TI and T2
Diabetes
Mellitus—a Promising Therapeutic Target and Plenary Lecture: The
Future Regulatory Environment for Metabolic Drugs—Sorting through
the Good, the Bad, and the Ugly. For more information and to register – [Link]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
KMI’s emphasis is on—
meeting unmet clinical need with products that work deep at
the mechanistic roots of disease and have potential for high impact. |
|
|
|
|
|
|
|
|
|
